Tucidinostat

Generic Name: Tucidinostat

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₉FN_₄O_₂

CAS Number: 1616493-44-7

Unique Ingredient Identifier: 87CIC980Y0

Indication: Investigated for use/treatment in cancer/tumors (unspecified).

Clinical Trials

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

Phase 2

Not yet recruiting

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: QL1706
Drug: Chidamide
Drug: Gemcitabine
Drug: Nab-paclitaxel

First Posted Date: 2025-04-30

Last Posted Date: 2025-04-30

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 33

Registration Number: NCT06951997

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Phase 3

Not yet recruiting

Conditions: Lymphoma, T-Cell, Peripheral

Interventions: Drug: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)
Drug: Tucidinostat
Drug: Placebo

First Posted Date: 2025-04-27

Last Posted Date: 2025-04-27

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 224

Registration Number: NCT06947967

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma

Phase 1

Not yet recruiting

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: chidamide and golidocitinib

First Posted Date: 2025-01-03

Last Posted Date: 2025-01-03

Lead Sponsor: Peking University Cancer Hospital & Institute

Target Recruit Count: 45

Registration Number: NCT06757387

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Phase 2

Recruiting

Conditions: Solid Tumor
Precision Medicine

Interventions: Drug: Olaparib tablet
Drug: Target Gene
Drug: Temozolomide capsule
Drug: Anlotinib
Drug: Trametinib tablet
Drug: Dabrafenib
Drug: Vebreltinib Enteric Capsules
Drug: Alpelisib Pill
Drug: Sacituzumab Govitecan-Hziy 180 MG
Drug: Lenvatinib Capsules
Drug: Pazopanib Pill
Drug: Palbociclib Pill
Drug: Chidamide
Drug: PD-1/PD-L1/PD-1&CTLA4 inhibitor

First Posted Date: 2024-12-18

Last Posted Date: 2024-12-18

Lead Sponsor: Tianjin Medical University Second Hospital

Target Recruit Count: 300

Registration Number: NCT06739395

Locations: 🇨🇳
Tianjin Medical Unversity Second Hospital, Tianjin, Tianjin, China

HDAC Inhibitor Combination with Chemoimmunotherapy in the Neoadjuvant Treatment of PMMR Locally Advanced Colon Cancer

Phase 2

Recruiting

Conditions: Colon Adenocarcinoma

Interventions: Drug: Chidamide + Tislelizumab + chemotherapy (CapeOX )
Drug: CapeOX

First Posted Date: 2024-11-28

Last Posted Date: 2024-11-28

Lead Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Target Recruit Count: 100

Registration Number: NCT06709885

Locations: 🇨🇳
Daping Hospital， Third Military Medical University, Chongqing, Chongqing, China

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Fruquintinib
Drug: Sintilimab
Drug: Chidamide

First Posted Date: 2024-11-12

Last Posted Date: 2024-11-20

Lead Sponsor: Dai, Guanghai

Target Recruit Count: 46

Registration Number: NCT06685276

Locations: 🇨🇳
China PLAGH, Beijing, China

Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma

Phase 2

Recruiting

Conditions: Sarcoma,Soft Tissue
Sarcoma
Sarcoma of Bone

Interventions: Drug: Chidamide Tablets combined with AK112

First Posted Date: 2024-10-11

Last Posted Date: 2024-10-11

Lead Sponsor: Shanxi Province Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT06637007

Locations: 🇨🇳
Shanxi Cancer Hospital, Taiyuan, Shanxi, China

Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

Phase 2

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma-Refractory
Diffuse Large B-Cell Lymphoma-Recurrent

Interventions: Drug: Glofitamab
Drug: Chidamide

First Posted Date: 2024-08-26

Last Posted Date: 2025-03-13

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 22

Registration Number: NCT06570447

Locations: 🇨🇳
Tianjin Medical University Cancer Insititute & Hospital, Tianjin, Tianjin, China

Exploration of Dalpiciclib + Tucidinostat in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

Phase 2

Not yet recruiting

Conditions: HR+/HER2- Advanced Breast Cancer

Interventions: Drug: Dalpiciclib
Drug: Tucidinostat

First Posted Date: 2024-08-16

Last Posted Date: 2024-08-16

Lead Sponsor: Beijing 302 Hospital

Target Recruit Count: 155

Registration Number: NCT06556862

Locations: 🇨🇳
The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China

A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL).

Phase 2

Active, not recruiting

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: Chidamide

First Posted Date: 2024-08-13

Last Posted Date: 2024-08-29

Lead Sponsor: The First Hospital of Jilin University

Target Recruit Count: 35

Registration Number: NCT06550336

Locations: 🇨🇳
The First Bethune Hospital of Jilin University, Changchun, Jilin, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy